FDANews
FDAnews Device Daily Bulletin

New York Attorney General Probes Mylan EpiPen School Contracts

Sept. 14, 2016

The pressure keeps mounting on Mylan for its EpiPen pricing practices, and now the New York attorney general’s office is investigating whether Mylan engaged in anticompetitive practices when entering contracts to sell its allergy therapy EpiPen to schools.

New York Attorney General Eric Schneiderman contends the company may have included anticompetitive terms in sales contracts, after a preliminary investigation of EpiPen sales indicated that several local school systems may have reached such agreements.

Those initial findings prompted a complete investigation into the company’s contracts with schools, the attorney general said. — José Vasquez

View today's stories